title: Evaluation of the effect of orally administered acid suppressants on intragastric pH in cats.
abstract: BACKGROUND
  Acid suppressant drugs are a mainstay of treatment for cats with gastrointestinal erosion and ulceration. However, clinical studies have not been performed to compare the efficacy of commonly PO administered acid suppressants in cats.
  
  
  OBJECTIVE
  To compare the effect of PO administered famotidine, fractionated omeprazole tablet (fOT), and omeprazole reformulated paste (ORP) on intragastric pH in cats. We hypothesized that both omeprazole formulations would be superior to famotidine and placebo.
  
  
  METHODS
  Six healthy adult DSH colony cats.
  
  
  METHODS
  Utilizing a randomized, 4-way crossover design, cats received 0.88-1.26 mg/kg PO q12h fOT, ORP, famotidine, and placebo (lactose capsules). Intragastric pH monitoring was used to continuously record intragastric pH for 96 hours beginning on day 4 of treatment. Plasma omeprazole concentrations at steady state (day 7) were determined by high performance liquid chromatography (HPLC) with ultraviolet detection. Mean percentage time that intragastric pH was ≥ 3 and ≥ 4 were compared among groups using ANOVA with a posthoc Tukey-Kramer test (α = 0.05).
  
  
  RESULTS
  The mean percentage time ± SD that intragastric pH was ≥ 3 was 68.4 ± 35.0% for fOT, 73.9 ± 23.2% for ORP, 42.8 ± 18.6% for famotidine, and 16.0 ± 14.2% for placebo. Mean ± SD plasma omeprazole concentrations were similar in cats receiving fOT compared to those receiving ORP and in a range associated with acid suppression reported in other studies.
  
  
  CONCLUSIONS
  These results suggest that both omeprazole formulations provide superior acid suppression in cats compared to famotidine or placebo. Fractionated enteric-coated OT is an effective acid suppressant despite disruption of the enteric coating.
authors.affiliation: Department of Small Animal Clinical Sciences, University of Tennessee College of Veterinary Medicine, Knoxville, TN.
authors.forename: S
authors.initials: S
authors.lastname: Parkinson
authors.forename: K
authors.initials: K
authors.lastname: Tolbert
authors.forename: K
authors.initials: K
authors.lastname: Messenger
authors.forename: A
authors.initials: A
authors.lastname: Odunayo
authors.forename: M
authors.initials: M
authors.lastname: Brand
authors.forename: G
authors.initials: G
authors.lastname: Davidson
authors.forename: E
authors.initials: E
authors.lastname: Peters
authors.forename: A
authors.initials: A
authors.lastname: Reed
authors.forename: M G
authors.initials: MG
authors.lastname: Papich
mesh_terms: D000818:Animals; D000863:Antacids / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*; D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000494:pharmacology; D019540:Area Under Curve; D002415:Cats / Q000502:physiology*; D018592:Cross-Over Studies; D015738:Famotidine / Q000494:pharmacology*; D006207:Half-Life; D006863:Hydrogen-Ion Concentration; D008991:Monitoring, Physiologic / Q000295:instrumentation / Q000662:veterinary; D009824:Ointments; D009853:Omeprazole / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*; D013270:Stomach / Q000502:physiology*; D013607:Tablets
chemical_list: D000863:Antacids; D000897:Anti-Ulcer Agents; D009824:Ointments; D013607:Tablets; D015738:Famotidine; D009853:Omeprazole
keywords: Bravo monitoring; Famotidine; Feline; Omeprazole